Veru Inc Dividendenrendite
Was ist das Dividendenrendite von Veru Inc?
Dividendenrendite von Veru Inc ist 0.00%
Was ist die Definition von Dividendenrendite?
Die Dividendenrendite stellt das Verhältnis zwischen den an die Aktionäre ausgeschütteten Dividenden je Aktie und dem Marktpreis je Aktie über ein zurückliegendes Jahr dar.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Dividendenrendite von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Veru Inc
Was macht Veru Inc?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Unternehmen mit dividendenrendite ähnlich Veru Inc
- Veru Inc hat Dividendenrendite von 0.00%
- The Monks Investment Trust Plc hat Dividendenrendite von 0.00%
- Crestwood Equity Partners LP hat Dividendenrendite von 0.00%
- Veritas (India) hat Dividendenrendite von 0.00%
- Pacific Horizon Investment Trust Plc hat Dividendenrendite von 0.01%
- AVI Global Trust plc hat Dividendenrendite von 0.01%
- Artemis Alpha Trust plc hat Dividendenrendite von 0.01%